Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.

PURPOSE: Tumor necrosis treatment (TNT) uses degenerating tumor cells and necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in animal tumor models and clinical trials have demonstrated that when linked to the therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in advanced lung cancer patients were studied in this pivotal registration trial. PATIENTS AND METHODS: Patients with advanced lung cancer were treated with systemic or intratumoral injection of (131)I-chTNT in eight oncology centers in China. The objective response rate (ORR) was assessed as the primary end point. RESULTS: All 107 patients who were entered onto the study and completed therapy had experienced treatment failure after prior radiotherapy or chemotherapy a mean of three times. The results showed an ORR of 34.6% (complete response, 3.7%; partial response, 30.8%; no change, 55.1%; and progressive disease, 10.3%) in all patients and 33% in 97 non-small-cell lung cancer patients. A biodistribution study demonstrated excellent localization of the radioactivity in tumors in both systemically and intratumorally injected patients. The most obvious adverse side effect was mild and reversible bone marrow suppression. CONCLUSION: Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used systemically or locally to treat refractory tumors of the lung.     

STAT1对人肾透明细胞癌放射敏感性的影响

目的 研究人肾透明细胞癌信号传递和转录活化因子1(STAT1)表达情况及抑制STAT1对该肿瘤细胞放射敏感性的影响.方法 采用免疫组织化学染色技术对比检测34例人肾透明细胞癌标本和12例正常肾组织标本的STAT1表达.用Western blotting法检测离体培养人肾透明细胞癌细胞(CRL-1932)、纤维母细胞(CCL-116)和wilm's瘤细胞(CRL-1441)的STAT1表达.用氟达拉滨和siRNA抑制CRL-1932细胞STAT1表达,并通过成克隆法和台盼蓝染色计数法研究抑制STAT1对CRL-1932细胞放射敏感性的影响.结果 人肾透明细胞癌标本的总STAT1和磷酸化STAT1表达均明显高于正常肾组织.Western blotting法显示CRL-1932细胞STAT1表达比CRL-1441、CCL-116细胞明显增高;药物氟达拉滨能显著抑制CRL-1932细胞磷酸化STAT1的表达,并显著增加CRL-1932细胞的放射敏感性,且放射增敏程度与药物浓度呈正相关.经STAT1 siRNA处理后CRL-1932细胞总STAT1和磷酸化STAT1的表达均被有效抑制,且细胞在照射后的存活分数显著下降.结论 肾透明细胞癌STAT1呈高表达,抑制STAT1对该细胞有放射增敏作用.     

p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.

PURPOSE: Recent studies have highlighted that the p53 codon 72 polymorphism plays a crucial role in modulating wild-type p53 apoptotic capacity, and as such may influence the response to chemotherapy. Thus, the purpose of this study was to investigate whether the p53 codon 72 polymorphism might influence pathologic response to neoadjuvant chemotherapy in primary breast cancer. EXPERIMENTAL DESIGN: One hundred and ten operable breast cancer patients received anthracycline-based neoadjuvant chemotherapy and p53 codon 72 polymorphism status was analyzed by PCR-RFLP. RESULTS: The distribution of initial clinical stage, tumor size, estrogen receptor or progesterone receptor status, menopausal status, or erbB2 expression was not significantly different among the polymorphic variants. However, we found that only 13% (3 of 23) of patients with the Pro/Pro variant had a good pathologic response, defined as a complete pathologic response or minimal residual disease. In comparison, 40% (22 of 55) or 37.5% (12 of 32) of patients with the Pro/Arg or Arg/Arg variant had a good pathologic response (P = 0.019). Moreover, patients with the Pro/Pro variant were more likely to have a positive axillary lymph node status than those with the Pro/Arg or Arg/Arg variant (P = 0.007). Furthermore, in multivariate analysis, p53 codon 72 polymorphism was found to be a strong predictor of pathologic response (odds ratio 6.7, 95% confidence interval, 1.4-31.2; P = 0.016). CONCLUSION: Our study indicates that breast cancer patients with the Pro/Pro variant may be less sensitive to anthracycline-based treatment than those with the Pro/Arg or Arg/Arg variant and suggests that analysis of p53 codon 72 polymorphism may provide a simple predictive marker for selecting the right breast cancer patients to anthracycline-based neoadjuvant chemotherapy in clinical setting.     

浅谈比较广告在医药行业的使用策略

目 的:探讨比较广告在医药行业的使用策略。方法:分析比较广告的优点和不足,结合实例提出比较广告在医药行业的 使用策略。结果与结论:只有结合实际,合理选择策略且独辟蹊径、力图创新,才能真正发挥比较广告应有的作用。     

HPLC荧光法测定血浆替米沙坦浓度

目的:建立高效液相-荧光检测法测定血浆替米沙坦浓度.方法:采用Symmetry C18柱,流动相:0.05 mol·L-1磷酸二氢钾溶液(用1 mol·L-1磷酸溶液调节pH=3.65):乙腈=55:45,激发波长:300nm;发射波长:385 nm.结果:线性回归方程y=0.055 80C-0.001 45,r=0.999 8;线性范围为1.0～500.0 μg·L-1,最低检测限为1 tμg·L-1.低、中、高三种浓度的绝对回收率分别为77.6%,94.97%和97.66%,相对回收率为96.62%,98.46%和104.43%,日内,日间RSD均小于10%.结论:该法操作简便,精密度高,可满足生物利用度试验方法学的要求.     

卟啉及其类似物在HPLC固定相中的应用

介绍了卟啉及其类似物衍生固定相的特征和制法,综述了这类固定相在HPLC中的应用和分离机制.     

阿米洛利的神经保护作用

阿米洛利是一种上皮细胞钠离子通道(ENaC)阻滞药,作为一种保钾利尿药已在临床应用了数十年.研究表明,中枢神经系统的多种离子通道对阿米洛利敏感,如酸敏感离子通道(ASIC)、Na+/H+交换泵等.这些通道具有重要的生理功能,而且还可能参与了脑缺血、组织酸中毒等病理学过程.阿米洛利通过阻滞这些通道,呈现出减轻缺血和酸化介导的神经元损伤等效应,很有可能成为治疗脑缺血等的新型神经保护剂.     

A novel robust nomogram based on peripheral monocyte counts for predicting lymph node metastasis of prostate cancer

Accurate methods for identifying pelvic lymph node metastasis(LNM)of prostate cancer(PCa)prior to surgery are still lacking.We aimed to investigate the predicti...     

符合临床要求的烤瓷镍铬合金镀金技术最佳工艺参数的研究

目的:探索符合临床要求的烤瓷镍铬合金最佳镀金工艺参数。方法:根据不同参数组合将试件分为8组,每组8片,其中6片用显微观测划痕法测量镀金层的临界载荷,并用扫描电镜观察镀层截面的质地和厚度,剩余2片用牙刷磨耗试验法测试镀金层的耐磨性能。综合评价后得出符合临床要求的最佳工艺参数。结果:镀金层的临界载荷随镀金时间的增加先增大再减小;镀金电压为0.9V时随着镀金时间的增加,镀金层致密性明显增加而厚度增加不明显,镀金电压为1.0V时随着镀金时间的增加镀金层的致密性和厚度均有明显增加;参数为1.0V360s时镀金层耐磨性能最佳。结论:1.0V360s是符合临床要求的烤瓷镍铬合金镀金技术最佳工艺参数。